What does DR PHARMA do?

DR PHARMA is a pharmacy in Bièvre. Private Limited, started on 17 December 2021, 1 establishment.

What is the address of DR PHARMA?

The registered office of DR PHARMA is located at Rue de Bouillon 17, 5555 Bièvre.

Is DR PHARMA still active?

Yes. According to the CBE (29 October 2026) DR PHARMA is active, legal situation “Normale toestand”, started on 17 December 2021.

Is DR PHARMA registered on Peppol?

Yes, DR PHARMA is registered on the Peppol network with ID 0208:0778778554.

What is the enterprise number of DR PHARMA?

The enterprise number of DR PHARMA is BE0778778554.

When was DR PHARMA founded?

DR PHARMA was founded on 17 December 2021.

Who are the directors of DR PHARMA?

According to the 2025 annual accounts, the directors of DR PHARMA are: CYRILLE REGNIER.

Is DR PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 17 December 2021; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did DR PHARMA make in 2025?

DR PHARMA posted a profit after taxes of € 112,169 in financial year 2025.

What is the revenue of DR PHARMA?

As a small company, DR PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 120,788.

DR PHARMA (Private Limited) - Bièvre - BE0778778554

Dossier DR PHARMA, printed on 29 October 2026 from databakkes.be/en/0778778554/dr-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 4 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

DR PHARMA from Bièvre, company number BE0778778554, closed financial year 2025 with a result of € 112,169 after tax. For that financial year DR PHARMA recorded a gross margin of € 120,788 and equity of € 591,990. Compared with financial year 2024, the result moved from € 309,201 to € 112,169. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 10, 2026.

What it is worth Growing

€ 591,990

▲ 23% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 112,169

▼ 64% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 18,670

▲ € 14,589 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 586,990.

Debts at end 2025

Bank debt ≈ 8 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 1.2 million

▼ 10% vs 2024

€ 138,871 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.

Owed to suppliers

€ 1,222

▲ € 917 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 38,441

▲ 9% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 91,172 Gross margin 2022: € 91,172 First fiscal year in the series	€ 126,504 Gross margin 2023: € 126,504 ▲ 39% vs 2022 (€ 91,172) Favourable step	€ 118,554 Gross margin 2024: € 118,554 ▼ 6% vs 2023 (€ 126,504) Unfavourable step	€ 120,788 Gross margin 2025: € 120,788 ▲ 2% vs 2024 (€ 118,554) Favourable step	▲ 2%
Profit after taxes	€ 43,063 Profit after taxes 2022: € 43,063 First fiscal year in the series	€ 122,557 Profit after taxes 2023: € 122,557 ▲ 185% vs 2022 (€ 43,063) Favourable step	€ 309,201 Profit after taxes 2024: € 309,201 ▲ 152% vs 2023 (€ 122,557) Favourable step	€ 112,169 Profit after taxes 2025: € 112,169 ▼ 64% vs 2024 (€ 309,201) Unfavourable step	▼ 64%
Equity	€ 48,063 Equity 2022: € 48,063 First fiscal year in the series	€ 170,620 Equity 2023: € 170,620 ▲ 255% vs 2022 (€ 48,063) Favourable step	€ 479,821 Equity 2024: € 479,821 ▲ 181% vs 2023 (€ 170,620) Favourable step	€ 591,990 Equity 2025: € 591,990 ▲ 23% vs 2024 (€ 479,821) Favourable step	▲ 23%
Total debts	€ 2,094,681 Total debts 2022: € 2,094,681 First fiscal year in the series	€ 1,963,293 Total debts 2023: € 1,963,293 ▼ 6% vs 2022 (€ 2,094,681) Favourable step	€ 1,653,929 Total debts 2024: € 1,653,929 ▼ 16% vs 2023 (€ 1,963,293) Favourable step	€ 1,556,437 Total debts 2025: € 1,556,437 ▼ 6% vs 2024 (€ 1,653,929) Favourable step	▼ 6%
Cash	€ 17,211 Cash 2022: € 17,211 First fiscal year in the series	€ 4,333 Cash 2023: € 4,333 ▼ 75% vs 2022 (€ 17,211) Unfavourable step	€ 4,082 Cash 2024: € 4,082 ▼ 6% vs 2023 (€ 4,333) Unfavourable step	€ 18,670 Cash 2025: € 18,670 ▲ € 14,589 vs 2024 (€ 4,082) Favourable step	▲ € 14,589
Retained profit	€ 43,063 Retained profit 2022: € 43,063 First fiscal year in the series	€ 165,620 Retained profit 2023: € 165,620 ▲ 285% vs 2022 (€ 43,063) Favourable step	€ 474,821 Retained profit 2024: € 474,821 ▲ 187% vs 2023 (€ 165,620) Favourable step	€ 586,990 Retained profit 2025: € 586,990 ▲ 24% vs 2024 (€ 474,821) Favourable step	▲ 24%
Bank debt	€ 1,578,602 Bank debt 2022: € 1,578,602 First fiscal year in the series	€ 1,444,664 Bank debt 2023: € 1,444,664 ▼ 8% vs 2022 (€ 1,578,602) Favourable step	€ 1,309,149 Bank debt 2024: € 1,309,149 ▼ 9% vs 2023 (€ 1,444,664) Favourable step	€ 1,171,942 Bank debt 2025: € 1,171,942 ▼ 10% vs 2024 (€ 1,309,149) Favourable step	▼ 10%
Balance sheet total	€ 2,142,744 Balance sheet total 2022: € 2,142,744 First fiscal year in the series	€ 2,133,913 Balance sheet total 2023: € 2,133,913 Unchanged (€ 2,142,744) Unchanged	€ 2,133,750 Balance sheet total 2024: € 2,133,750 Unchanged (€ 2,133,913) Unchanged	€ 2,148,427 Balance sheet total 2025: € 2,148,427 ▲ 1% vs 2024 (€ 2,133,750) Unchanged	▲ 1%

Key figures of DR PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to DR PHARMA?

What happened at DR PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 10, 2026 New annual accounts for financial year 2025: profit of € 112,169 (▼ 64% vs 2024). Source: NBB ↗
Dec 17, 2021 New establishment in Bièvre. KBO
Dec 17, 2021 Start of the company according to the CBE. KBO

In short

From € 43,063 profit in 2022 to € 112,169 profit in 2025.

Paid € 74,324 in corporate taxes since 2022.

Best year ever: 2024, with € 309,201 profit.

Original PDFs at the National Bank ↗

Management

CYRILLE REGNIER

DR PHARMA

PHARDEN 100%

Behind DR PHARMA is CYRILLE REGNIER. It owns 100% of PHARDEN itself.

Directors

According to the 2025 annual accounts

CYRILLE REGNIER

Director

Also active at: PHARDEN

Establishments

Establishment units

Physical locations of this company

Registered office

Rue de Bouillon 17

5555 Bièvre

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

PHARDEN same network

€ 609,302 gross margin · 2025

Cabinet Médical Camille Dumonceaux

€ 128,237 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0778.778.554
VAT number: BE 0778.778.554
Registered office: Rue de Bouillon 17, 5555 Bièvre
Names & denominations: DR PHARMA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 17 December 2021
Peppol: Active · Active since 16 Feb 2026
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗